10 results on '"Trabacchi E"'
Search Results
2. Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.
- Author
-
Gugliotta G, Castagnetti F, Breccia M, Levato L, Intermesoli T, D'Adda M, Salvucci M, Stagno F, Rege-Cambrin G, Tiribelli M, Martino B, Bocchia M, Cedrone M, Trabacchi E, Cavazzini F, Porretto F, Sorà F, Simula MP, Albano F, Soverini S, Foà R, Pane F, Cavo M, Saglio G, Baccarani M, and Rosti G
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Humans, Middle Aged, Progression-Free Survival, Treatment Outcome, Young Adult, Leukemia, Myeloid, Chronic-Phase drug therapy, Pyrimidines adverse effects
- Abstract
We report the final analysis, with a 10-year follow-up, of the phase II study GIMEMA CML 0307 (NCT00481052), which enrolled 73 adult patients (median age 51 years; range, 18-83) with newly diagnosed chronic-phase chronic myeloid leukemia to investigate the efficacy and the toxicity of front-line treatment with nilotinib. The initial dose was 400 mg twice daily; the dose was reduced to 300 mg twice daily as soon as this dose was approved and registered. The 10-year overall survival and progression- free survival were 94.5%. At the last contact, 36 (49.3%) patients were continuing nilotinib (22 patients at 300 mg twice daily, 14 at lower doses), 18 (24.7%) patients were in treatment-free remission, 14 (19.2%) were receiving other tyrosinekinase inhibitors and four (5.5%) patients have died. The rates of major and deep molecular responses by 10 years were 96% and 83%, respectively. The median times to major and deep molecular response were 6 and 18 months, respectively. After a median duration of nilotinib treatment of 88 months, 24 (32.9%) patients discontinued nilotinib while in stable deep molecular response. In these patients, the 2-year estimated treatment-free survival was 72.6%. The overall treatment-free remission rate, calculated on all enrolled patients, was 24.7% (18/73 patients). Seventeen patients (23.3%), at a median age of 69 years, had at least one arterial obstructive event. In conclusion, the use of nilotinib front-line in chronic phase chronic myeloid leukemia can induce a stable treatment-free remission in a relevant number of patients, although cardiovascular toxicity remains of concern.
- Published
- 2022
- Full Text
- View/download PDF
3. Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.
- Author
-
Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, Soverini S, Cavo M, Martinelli G, Alimena G, Pane F, Saglio G, Rosti G, and Baccarani M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose drug effects, Cholesterol blood, Female, Humans, Leukemia, Myeloid, Chronic-Phase blood, Male, Middle Aged, Protein Kinase Inhibitors therapeutic use, Pyrimidines adverse effects, Remission Induction methods, Thrombosis chemically induced, Treatment Outcome, Triglycerides blood, Young Adult, Leukemia, Myeloid, Chronic-Phase drug therapy, Pyrimidines administration & dosage
- Abstract
The introduction and the extended clinical use of nilotinib in the first-line treatment of chronic myeloid leukemia have been based on company-sponsored trials. Independent confirmations are extremely important. We report an investigator-sponsored study of nilotinib 300 mg twice daily in 130 chronic myeloid leukemia patients in early chronic phase. A deep molecular response was achieved in 46% (MR
4.0 ) and 17% (MR4.5 ) of patients at 2 years; 58% of the enrolled patients achieved a MR4.0 at least once, with a sustained MR4.0 in 52% of them. With a median observation of 29 months (range 24-37 months), 77% of patients were still on treatment with nilotinib. The reasons for permanent discontinuation were: 3% progression, 5% failure or suboptimal response, 8% adverse events, 1% treatment-free remission, and 5% other reasons. Thirteen thrombotic arterial events were reported in 12 patients. A prospective evaluation of metabolic effects showed an increase of fasting glucose without significant variations of glycated hemoglobin, an increase of total cholesterol (both low density lipoprotein and high density lipoprotein fractions) and a decrease of triglycerides. This study confirms a high and rapid efficacy of nilotinib 300 mg twice daily and provides detailed information on the type and incidence of non-hematologic and metabolic adverse events (clinicaltrials.gov identifier: 01535391)., (Copyright© Ferrata Storti Foundation.)- Published
- 2016
- Full Text
- View/download PDF
4. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.
- Author
-
Gugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, and Rosti G
- Subjects
- Adult, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Survival Rate, Imatinib Mesylate administration & dosage, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Pyrimidines administration & dosage
- Abstract
Nilotinib is a second-generation tyrosine kinase inhibitor that has been approved for the first-line treatment of chronic-phase chronic myeloid leukemia, based on the results of a prospective randomized study of nilotinib versus imatinib (ENESTnd). Apart from this registration study, very few data are currently available on first-line nilotinib treatment. We report here the long-term, 6-year results of the first investigator-sponsored, GIMEMA multicenter phase 2, single-arm trial with nilotinib 400 mg twice daily as first-line treatment in 73 patients with chronic-phase chronic myeloid leukemia. Six-year overall survival and progression-free survival rates were 96%, with one death after progression to blast phase. At 6 years, 75% of the patients were still on nilotinib. The cumulative incidence of major molecular response was 98%; only one patient had a confirmed loss of major molecular response. The cumulative incidence of deep molecular response (MR 4.0) was 76%. Deep molecular response was stable (≥ 2 years) in 34% of these patients. Cardiovascular adverse events, mainly due to arterial thrombosis, occurred in 11/73 patients (15%), after 24 to 76 months of therapy. They were more frequent in elderly patients, and in those with baseline cardiovascular risk factors. None was fatal, although there was a relevant morbidity. This is the study with the longest follow-up of a high dose of nilotinib (400 mg twice daily): it highlights the high efficacy and the cardiovascular toxicity of the drug (CTG.NCT.00481052)., (Copyright© Ferrata Storti Foundation.)
- Published
- 2015
- Full Text
- View/download PDF
5. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
- Author
-
Santachiara R, Maffei R, Martinelli S, Arcari A, Piacentini F, Trabacchi E, Alfieri P, Ferrari A, Leonardi G, Luppi G, Longo G, Vallisa D, Marasca R, and Torelli G
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Benzamides, Female, Humans, Imatinib Mesylate, Immunoglobulins therapeutic use, Male, Middle Aged, Retrospective Studies, gamma-Globulins therapeutic use, Agammaglobulinemia chemically induced, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Gastrointestinal Stromal Tumors drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Piperazines adverse effects, Piperazines therapeutic use, Pyrimidines adverse effects, Pyrimidines therapeutic use
- Abstract
Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few immune alterations are described in humans. We retrospectively studied hematologic and immunological parameters in 72 chronic myeloid leukemia and 15 gastrointestinal stromal tumor patients treated with imatinib at standard dosage and in 20 chronic myeloid leukemia patients treated before the introduction of imatinib in clinical practice. Both chronic myeloid leukemia and gastrointestinal stromal tumor patients developed a significant reduction of gammaglobulin and immunoglobulin serum levels. No significant hypogammaglobulinemia was observed in chronic myeloid leukemia patients in the pre-imatinib era. These data demonstrate that imatinib treatment induces hypogammaglobulinemia that can reach a severe entity in 10% of cases, both in chronic myeloid leukemia and in gastrointestinal stromal tumor patients. Prospective studies are needed to evaluate immune humoral alterations and to define the real incidence of infectious events, including viral reactivations.
- Published
- 2008
- Full Text
- View/download PDF
6. Primary pancreatic lymphoma. Report of five cases.
- Author
-
Arcari A, Anselmi E, Bernuzzi P, Bertè R, Lazzaro A, Moroni CF, Trabacchi E, Vallisa D, Vercelli A, and Cavanna L
- Subjects
- Aged, Biopsy, Biopsy, Needle, Female, Humans, Male, Middle Aged, Recurrence, Remission Induction, Retrospective Studies, Treatment Outcome, Lymphoma, Non-Hodgkin diagnosis, Lymphoma, Non-Hodgkin therapy, Pancreatic Neoplasms diagnosis, Pancreatic Neoplasms therapy
- Abstract
Primary pancreatic lymphoma (PPL) is a very rare disease. We report five cases of PPL (4 men and 1 woman, mean age 65 years) diagnosed and treated at our Institution from 1987 to 1997. None of these patients had evidence of extrapancreatic disease and they were categorized as PPL involving pancreas only (stage IE, 3 patients) or pancreas and peripancreatic lymph nodes (stage IIE, 2 patients). The most common presenting symptoms were abdominal pain and weight loss. Imaging techniques showed a mass of the pancreatic head in all cases. The histological diagnosis (3 diffuse-large cell non-Hodgkin's lymphoma and 2 lymphoplasmacytic lymphoma/immunocytoma) was made by ultrasound-guided fine needle aspiration biopsy and tissue core fine-needle biopsy in three patients and by surgery in the remaining two patients. The three patients diagnosed by percutaneous biopsy were treated with chemotherapy as front-line therapy and two of them received also local radiotherapy; one of these patients is still alive in complete remission at 69 months, one died of an unrelated disease at 67 months and one died of lymphoma relapse at 88 months. Two patients underwent pancreaticoduodenectomy plus adjuvant chemotherapy; one of them died of recurrent cholangitis 8 months after surgery while the other one is still alive in complete remission after 160 months. This study shows that: 1) imaging techniques can suggest the suspicion of PPL but are unable to distinguish PPL from pancreatic adenocarcinoma; 2) histological diagnosis can be easily obtained by percutaneous US-guided tissue core biopsy; 3) surgery can be avoided both for diagnosis and therapy but the treatment of choice of PPL may only be evaluated on a larger series of patients.
- Published
- 2005
7. Primary pancreatic lymphoma. A report of five cases.
- Author
-
Arcari A, Anselmi E, Bernuzzi P, Berta R, Lazzaro A, Moroni CF, Trabacchi E, Vallisa D, Vercelli A, and Cavanna L
- Subjects
- Adenocarcinoma diagnosis, Aged, Biopsy, Fine-Needle methods, Combined Modality Therapy, Diagnosis, Differential, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Leukemia, Lymphocytic, Chronic, B-Cell therapy, Lymphoma, Large B-Cell, Diffuse pathology, Lymphoma, Large B-Cell, Diffuse therapy, Pancreatic Neoplasms pathology, Pancreatic Neoplasms therapy
- Published
- 2005
8. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
- Author
-
Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, and Baccarani M
- Subjects
- Aged, Benzamides, Enzyme Inhibitors pharmacology, Exons genetics, HL-60 Cells, Humans, Hypereosinophilic Syndrome genetics, Imatinib Mesylate, Male, Oncogene Proteins, Fusion genetics, Piperazines pharmacology, Pyrimidines pharmacology, RNA Splicing, RNA, Messenger genetics, Remission Induction, Enzyme Inhibitors therapeutic use, Hypereosinophilic Syndrome drug therapy, Oncogene Proteins, Fusion antagonists & inhibitors, Piperazines therapeutic use, Pyrimidines therapeutic use, Receptor, Platelet-Derived Growth Factor alpha antagonists & inhibitors, Receptor, Platelet-Derived Growth Factor alpha genetics, mRNA Cleavage and Polyadenylation Factors antagonists & inhibitors, mRNA Cleavage and Polyadenylation Factors genetics
- Published
- 2004
9. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia.
- Author
-
Rosti G, Trabacchi E, Bassi S, Bonifazi F, de Vivo A, Martinelli G, Alberti D, Fincato G, Saglio G, and Baccarani M
- Subjects
- Adolescent, Adult, Aged, Benzamides, Cytogenetic Analysis, Humans, Imatinib Mesylate, Interferon alpha-2, Leukemia, Myelogenous, Chronic, BCR-ABL Positive diagnosis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Middle Aged, Piperazines therapeutic use, Pyrimidines therapeutic use, Recombinant Proteins, Risk Assessment, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Interferon-alpha therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Polyethylene Glycols
- Abstract
Background and Objectives: We compared the early cytogenetic response (CgR) to a combination of imatinib mesylate (Glivec, Novartis Pharma, Basel, Switzerland) and a pegylated form of human recombinant interferon-alpha2b (pegIFN-alpha2b, PegIntron, Schering Plough, Kenilworth, New Jersey, USA) with the relative risk, either according to Sokal's or Euro scoring systems., Design and Methods: Seventy-seven patients with early chronic phase, previously untreated, Ph-positive chronic myeloid leukemia (CML) received a combination of imatinib mesylate (400 mg/day) and pegIFN-alpha2b (3 consecutive cohorts treated with 50, 100 or 150 mg/weekly). Fifty-seven patients have completed the first 6 months of treatment and are evaluable for CgR., Results: After 6 months of treatment, the overall major CgR rate was 89% and 90% in low risk patients (Sokal's and Euro, respectively), 76 and 59% in intermediate risk and 23% and 17% in high risk patients. These differences were significant (p=0.0001 for Sokal and 0.001 for e)., Interpretation and Conclusions: For the first time, these data suggest that the early CgR rate to a imatinib mesylate-based regimen is significantly risk-related.
- Published
- 2003
10. Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.
- Author
-
Amabile M, Giannini B, Testoni N, Montefusco V, Rosti G, Zardini C, Terragna C, Buonamici S, Ottaviani E, Soverini S, Fiacchini M, Bassi S, de Vivo A, Trabacchi E, Saglio G, Pane F, Baccarani M, Tura S, and Martinelli G
- Subjects
- Bone Marrow, Female, Humans, Male, Methods, Reverse Transcriptase Polymerase Chain Reaction standards, Sensitivity and Specificity, Genes, abl genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, RNA, Messenger analysis
- Abstract
Background and Objectives: The most common translocation in chronic myeloid leukemia (CML) t(9;22) (q34;q22) produces the BCR/ABL fusion gene. We set up and evaluated a rapid and reliable real-time reverse-transcription-polymerase chain reaction (RT-PCR) approach using TaqMan technology for detection and quantification of bcr-abl transcripts in CML patients at diagnosis and during therapy., Design and Methods: A pair of primers and probe complementary to ABL exon 2 were designed, enabling detection of the most frequent bcr-abl transcripts, and also of the normal ABL-Ia transcript as an internal control. Conditions were established to amplify less than 1(-10) target molecules/reaction and detect one CML cell in 10(6) cells from healthy donors. To determine the utility of the assay, we quantified the bcr-abl/ABL-Ia ratio in 59 bone marrow samples (45 samples with evidence of different Ph+ chromosome percentages and 14 samples in complete cytogenetic remission) from 48 CML patients, 34 of them at diagnosis and 14 in clinical remission (CR). In 14 cases, this ratio was compared with results obtained by a competitive-quantitative RT-PCR/capillary electrophoresis method from contemporary specimens., Results: By real-time RT-PCR, the median value of bcr-abl/ABL-Ia ratio at diagnosis was 15.334 (range 3.3-28.81) and fell to 0.9 (range 0.003-26.1) in CR. The median value of bcr-abl/ABL-Ia ratio at cytogenetic remission was 0.7 (range 0.003-2.83). The real-time bcr-abl/ABL-Ia ratios correlated with those obtained by competitive RT-PCR (p < 0.0001) and the percentage of Ph+ metaphases (p < 0.0001). The high sensitivity and specificity of the real-time RT-PCR procedure was confirmed in all 14 patients with minimal residual disease. INTERPRETATION AND CONCLUSIONS. We conclude that this real-time RT-PCR procedure is a reliable and sensitive method of monitoring CML patients after therapy, and that the bcr-abl/ABL-Ia ratio correlates strongly with cytogenetic analysis.
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.